Skip to main content
Figure 3 | BMC Musculoskeletal Disorders

Figure 3

From: Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats

Figure 3

A Zoledronate treated graft after 6 weeks. No marrow cavity has formed behind the ossification front but the graft trabeculas below are still remaining to a large extent. The total amount of bone, both newly formed and remaining graft bone is higher in the remodelled area compared to the control. (Hematoxylin Eosin × 20). B Magnification of the borderzone with retained trabeculas in the remodelled area.

Back to article page